TORONTO, Jan. 10, 2013 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) today
refiled its financial statements for the year ended September 30, 2012
to correct two oversights in the Consolidated Statements of
The previously filed Consolidated Statements of Comprehensive Loss had
properly reported total revenue, total expenses, and net loss per
share. However, the cost of goods sold reported for Virology products
and technologies was misstated and should have read $3,807,360 rather
than $2,502,288 for the year ending September 30, 2012, and $2,795,310
rather than $1,298,672 for the year ending September 30, 2011. Also,
the International Financial Reporting Standards adjustments for the
year ended September 30, 2011 was misstated as $5,391,611 and should
have read $5,598,445. All other information contained in the
previously filed financial statements for the year ended September 30,
2012 remains unchanged.
The refilled annual financial statements are available at www.SEDAR.com.
The Toronto Stock Exchange does not accept responsibility for the
adequacy or accuracy of this release.
About Microbix Biosystems Inc.
Microbix Biosystems Inc. specializes in the development of the most
advanced vaccine production technology and markets virology and
biological products worldwide. In addition, The Company has
intellectual property in large market biotherapeutic drugs, vaccine
technologies and animal reproduction technologies. Microbix supplies
customers in the U.S., Europe, and Asia. Established in 1988, Microbix
is headquartered in Toronto.
SOURCE: Microbix Biosystems Inc.
For further information:
Visit www.microbix.com or contact: Vaughn Embro-Pantalony, CEO, (416) 234-1624 x 350; or James Long, CFO, (416) 234-1624 x 265.